Dronabinol - Echo Pharmaceuticals

Drug Profile

Dronabinol - Echo Pharmaceuticals

Alternative Names: Delta(9)-tetrahydrocannabinol - Echo Pharmaceutical; Delta(9)-THC - Echo Pharmaceutical; ECP022A (delta9-THC); Namisol

Latest Information Update: 13 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Echo Pharmaceuticals
  • Developer Echo Pharmaceuticals; University Medical Centre of Nijmegen; VU University Medical Center
  • Class Antiemetics; Appetite stimulants; Cannabinoids; Muscle relaxants; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Alzheimer's disease; Multiple sclerosis; Pain

Highest Development Phases

  • Phase II Alzheimer's disease; Multiple sclerosis; Pain

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 19 Aug 2015 Primary adverse events data from all the clinical trials in Alzheimer's disease, Multiple sclerosis and Pain released by Echo Pharmaceuticals
  • 08 Aug 2015 Phase II development for Alzheimer's disease, Multiple sclerosis and Pain is ongoing in Netherlands
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top